Mario Cazzola - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Mario Cazzola's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Mario Cazzola
Verified
Associate Editor, Respiratory Medicine
Beats
Digital Health
Content
By Elena Pistocchini, Mario Cazzola, Paola Rogliani, Luigino Calzetta| Taylor & Francis@ ABSTRACTIntroduction The journey from initial drug discovery to approval for respiratory diseases typically spans approximately 10.4 years and cost over $2.8 billion. This intricate process involves five stages: target identification, therapeutic molecule discovery, preclinical testing, clinical trials, and regulatory approval.
Efficacy and safety of long-acting muscarinic antagonists in COPD: a meta-analysis and meta-regression with a focus on aging
By Elena Pistocchini, Mario Cazzola, Paola Rogliani| Respiratory Medicine Verified KeywordsAgeingCOPDefficacylong-acting muscarinic antagonistmeta-analysismeta-regressionsafetyIntroductionThe global elderly population is increasing rapidly, with projections indicating that individuals aged 65 and over will constitute 20% of the total population by 2030 [1]. In healthy individuals, lung development and function peak at around 25 years of age, stabilize until about 35, and then decline with aging.
By Elena Pistocchini, Mario Cazzola, Paola Rogliani, Luigino Calzetta| Taylor & Francis@ ABSTRACTIntroduction The journey from initial drug discovery to approval for respiratory diseases typically spans approximately 10.4 years and cost over $2.8 billion. This intricate process involves five stages: target identification, therapeutic molecule discovery, preclinical testing, clinical trials, and regulatory approval.
Company Info
Respiratory Medicine
Rome, Lazio, Italy
+39 06 7259 6393